Measuring the Activated Clotting Time in patients receiving unfractionated heparin prior to coronary angiography and intervention. A single-centre validation study comparing different blood sampling sites

Measuring the Activated Clotting Time in patients receiving unfractionated heparin prior to coronary angiography and intervention. A single-centre validation study comparing different blood sampling sites - Validation of ACT measurements

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44549

Enrollment

100

Registered

2017-11-23

Start date

2018-01-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Consecutive patients scheduled for diagnostic coronary angiography or elective percutaneous coronary intervention (PCI) are screened for entry into this study. Patient are eligible for this study when it is expected that the scheduled procedure will be accomplished with a single bolus of heparin, i.e. patient undergoing a procedure with expected duration of > 1 hour will not be included in this study.

Exclusion criteria

Exclusion criteria: - Use of novel oral anticoagulants or vitamin K antagonists - Chronic use of non-steroid anti-inflammatory drugs with the exception of aspirin - Known renal insufficiency (e.g. serum creatinine level of more than 265 *mol/L (i.e. more than 3.5 mg/L)) - Liver function disorders with coagulopathies (PT >1.5N, INR >2.0 and/or thrombocyte count

Design outcomes

Primary

Measure	Time frame
Variability in ACT measurements at different blood sampling sites at the end of coronary angiography or intervention in patients receiving pre-procedural UFH.	—

Secondary

Measure	Time frame
N.A.	—

Countries

Netherlands

Outcome results